Thursday, Vor Biopharma Inc. ( VOR ) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg. Pfizer Inc’s Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients two years and older....

12:33 PM EDT, 09/06/2024 (MT Newswires) -- (Updates with details throughout.) Esmark and its founder and former Chief Executive James Bouchard agreed to pay $600,000 to settle charges the company launched a bid for US Steel (X) while lacking the financial means to do so, the US Securities and Exchange Commission said Friday. Esmark and Bouchard will pay civil money...

Sept 6 (Reuters) - Elis SA: * CONFIRMS IT HAS MADE A PRELIMINARY APPROACH TO VESTIS REGARDING A POTENTIAL ACQUISITION * THERE CAN BE NO ASSURANCE THAT THESE DISCUSSIONS WILL RESULT IN SIGNING OF A TRANSACTION OR OTHER AGREEMENT * ANY TRANSACTION, SHOULD ONE BE AGREED, WOULD BE IN LINE WITH ELIS' COMMITMENTS TO ITS SHAREHOLDERS Source text for Workspace:...

12:33 PM EDT, 09/06/2024 (MT Newswires) -- (Updates to add stock move in the first paragraph.) Guidewire Software ( GWRE ) shares advanced by more than 11% in recent Friday trading after the company released fiscal Q4 results that exceeded market expectations. The company reported fiscal Q4 non-GAAP earnings late Thursday of $0.62 per diluted share, down from $0.74 a...